Our Vision

Transforming blood test through technology innovation

As we enter the age of personalized medicine, DNA sequencing is playing an increasingly important role in determining a patient’s optimal treatment plan. Unfortunately, acquiring tumor to sequence often requires performing a tissue biopsy which can be painful, dangerous, and sometimes even impossible, as is the case with both metastatic and early stage cancer. Liquid biopsy, however, offers a viable non-invasive alternative to tissue biopsy. Not only is liquid biopsy minimally stressful for patients, but is also more comprehensive and easily performed at regular intervals. The potential applications of liquid biopsy are vast -- from targeted cancer therapy selection to real-time minimal residual disease monitoring to population-level early screening -- and we believe it will play a critical role in the future of cancer management.

Our Impacts

What We Do

Advancing technology

We make necessary technical advancement to a robust assay

Developing clinical tests

We address unmet clinical needs through partnership with research community

Partnering with the leaders

We work with experts to accelerate product development and clinical adoption

Our Vision

Inventing the future of cancer diagnostics.

For each project we establish relationships with partners who we know will help us create added value for your project. As well as bringing together the public and private sectors, we make sector-overarching links to gather knowledge and to learn from each other. The way we undertake projects is based on permanently applying values that reinforce each other: sociocultural value, experimental value, building-technical value and economical value.

Heading

Our Advantages

Proprietary Technology


AccuraGen uniquely employs rolling-circle amplification to perform consensus-based concatemer error correction. The fundamental of our technology ensures a high conversion rate and minimizes the proliferations of errors.  We optimized our assay to detect a breadth of genetic alterations with a sensitivity approaching the physical limit and a specificity as much as 100x better than benchmark.

Multidisciplinary efforts

Challenging the boundaries, robust results

When our assay is approaching the phsyical limit, we take every bit of efforts to ensure a consistent and robust result. Our multidisciplinary team that spans across mathematics, statistics, computer science, clinical science, genomics, all work together to convert minute of cancer signals in the blood to actionable diagnotics-grade information with meaningful clinical economics.

Our Approach

What We Do

Experiment

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla.

Sequence

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros. Lorem ipsum dolor sit amet consectetur.

Analyze

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare.

Our Advantage

Proprietary on technology.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Successful Properties

Complex process, powerful results.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Meet Our Team

Maecenas egestas arcu quis ligula mattis placerat. Etiam imperdiet imperdiet orci. Praesent nonummy enue habitant morbi.

Learn More
Leadership

Board of Directors

Ying Kang

Chief Executive Officer

Min Cui, PhD

Managing Director of DeCheng Capital

Dan Zabrowski, PhD

Venture Partner of DeCheng Capital; ex-President of Roche Sequencing and Tissue Diagnostics

Kelvin Liu

General Manager of Junson Capital

Wei Xu

Executive Partner of Denlux Capital

Backed by
Top Investors

Join Our Team

Latest Publications

Shanghai Yunsheng Medical Laboratory joined the Inclusive Medical Association

Shanghai Yunsheng Medical Laboratory under AccuraGen Holdings participated in the launch of the Inclusive Medical Association, leading the way in cancer gene sequencing technology. . .

Collaborator presented AccuraGen's ctDNA-NGS kit validation at AACR

On April 15, the American Association for Cancer Research (AACR)2018 annual meeting of the liquid biopsy sub-forum (mini symposium: liquid biopsy 1) gathered lots of experts. . .

Subscribe to our newsletter now.

Get our news and latest project, first.
In your mailbox. Monthly.

No spam, ever.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form